Biogen Allowance for doubtful accounts remained flat by 0.0% to $3.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 36.4%, from $2.20M to $3.00M. Over 3 years (FY 2022 to FY 2025), Allowance for doubtful accounts shows an upward trend with a 9.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increasing allowance relative to receivables may signal deteriorating customer credit quality or a weakening economic environment.
This is a contra-asset account that represents the estimated portion of accounts receivable that the company does not ex...
Standard accounting practice; peers in similar industrial sectors typically maintain reserves proportional to their credit risk profile.
other_allowance_for_doubtful_accounts_receivable_current| Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.30M | $2.00M | $2.40M | $2.40M | $2.40M | $3.10M | $2.20M | $2.20M | $2.20M | $3.00M | $3.00M |
| QoQ Change | — | -13.0% | +20.0% | +0.0% | +0.0% | +29.2% | -29.0% | +0.0% | +0.0% | +36.4% | +0.0% |
| YoY Change | — | -13.0% | — | — | — | +55.0% | -8.3% | -8.3% | -8.3% | -3.2% | +36.4% |